All In Biotech

Drug Trial Radar · NCT05541939

Effect of Mizagliflozin on Postprandial Glucose and Insulin in Post-Bariatric Hypoglycemia Subjects

Phase 2 Randomized Single Ascending Dose Study in Post-Bariatric Hypoglycemia Subjects to Determine the Effect of Mizagliflozin Formulations on Postprandial Glucose and Insulin Levels

Last checked: Nov 20, 2026Latest source record: Jun 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

9

Actual

Start

Sep 13, 2022

Primary completion

Feb 17, 2023

Study completion Feb 17, 2023

Sponsor

Lead sponsor
Vogenx, Inc.Industry
Sponsor type
Industry
First posted
Sep 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical study will examine the safety and tolerability, as well as the effects of orally administered mizagliflozin on post prandial glucose and insulin levels in subjects diagnosed with post-bariatric hypoglycemia (PBH).

Conditions

  • Postbariatric Hypoglycemia

Interventions

  • MizagliflozinDrug

    Encapsulated or Liquid Formulation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Glucose Nadir After Mizagliflozin DosingTime frame: 0-3 hours following liquid meal

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Stanford

    Palo Alto, California

  • University of Colorado / Anschutz Medical Campus

    Aurora, Colorado

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.